Eko

Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram (ECG) functionality to detect heart rhythm abnormalities using AI algorithms. The device also features noise cancellation and high-quality audio and color displays.

Eko Health's technology aims to reduce diagnostic bottlenecks and enhance patient outcomes by facilitating early detection of cardiac and pulmonary diseases. With over 500,000 healthcare professionals utilizing its FDA-cleared platform worldwide as of June 2024, the company has established a substantial presence in the market.

In 2020, the company obtained FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations. In April 2024, Eko obtained FDA 510(k) clearance for its AI-aided cardiac tool, Eko Low Ejection Fraction Tool (ELEFT).

In June 2023, Eko Health launched its next-generation digital stethoscope, CORE 500, featuring advanced capabilities such as a full-color display, 3-lead electrocardiogram (ECG), and TrueSound technology for optimal sound filtering. The CORE 500 received FDA 510(k) clearance and seamlessly integrates with the SENSORA platform.

Key customers and partnerships

In July 2023, the company partnered with pharmaceutical company Astellas to develop Z1608, a non-invasive device-DTx solution for heart failure patients.

In November 2023, Eko Health announced a large-scale deployment of its AI-enabled technology through the TRICORDER program, an implementation initiative led by Imperial College London and funded by the National Institute for Health and Care Research (NIHR). The program aims to deploy Eko's technology to 100 General Practitioner (GP) practices across the UK, assisting clinicians in evaluating heart failure, valvular heart disease, and atrial fibrillation.